Indoco Remedies is expected to report a top-line growth of 18.9% to Rs. 176cr. The OPM is expected to expand by 230bp yoy to 16.9%, driven by growth in domestic formulation sales. As a result, net profit is expected to increase by 81.0% yoy to Rs. 22.7cr on back of improvement in OPM.
We maintain our buy with a target of 89.
